Showing results (101-110 of 199) with videos related to
Sort By:
Pageof 20
American Journal of Hematology|September 30, 2011
A 10-year experience with treatment of high and standard risk Hodgkin disease: six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preservedEldad J Dann, Zeev Blumenfeld, Rachel Bar-Shalom, et al.Cancers|February 27, 2026
Surveillance of Smoldering Myeloma Patients Who Progress to Active Disease Is Associated with Favorable OutcomesGil Fridberg, Inbar Cohen, Renana Robinson, et al.Eclinicalmedicine|August 10, 2023
Clinical outcome and humoral immune responses of β-thalassemia major patients with severe iron overload to SARS-CoV-2 infection and vaccination: a prospective cohort studyHussam Ghoti, Hala Zreid, Israa Ghoti, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 17, 2009
(18)F-FDG avidity in lymphoma readdressed: a study of 766 patientsMichal Weiler-Sagie, Olga Bushelev, Ron Epelbaum, et al.Bone Marrow Transplantation|November 24, 2020
Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case seriesEfrat Luttwak, David Hagin, Chava Perry, et al.Therapeutic Advances in Hematology|August 11, 2021
Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective studyRoy Vitkon, Dan Netanely, Shai Levi, et al.Cancers|October 26, 2024
The Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft vs. Host Disease on Treatment Patterns and Outcomes-A Single-Center Longitudinal Cohort AnalysisGil Fridberg, Odelia Amit, Chen Karni, et al.Frontiers in Oncology|May 31, 2021
Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL CellsYamit Shorer Arbel, Ben-Zion Katz, Ronen Gabizon, et al.Haematologica|September 23, 2017
Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase studyPieternella Lugtenburg, Irit Avivi, Henriette Berenschot, et al.European Journal of Nuclear Medicine and Molecular Imaging|September 4, 2021
[18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studiesDan Cohen, Efrat Luttwak, Ofrat Beyar-Katz, et al.Pageof 20